drugset / Trial / NCT04460807
Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer
Phase 3
Terminated
23 enrolled
Ente Ospedaliero Ospedali Galliera
Federation of Italian Cooperative Oncology Groups · collabFondazione Policlinico Universitario Agostino Gemelli IRCCS · collabIstituto Di Ricerche Farmacologiche Mario Negri · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In this Italian, multicenter, randomized, double-blind, placebo controlled, phase III study the efficacy of exemestane will be evaluated in addition to the standard front line treatment in patients with hormone-receptor-positive high grade serous or endometrioid Epithelian Ovarian Cancer (EOC). The patients enrolled in the EXPERT trial will receive exemestane or placebo in addition to standard treatment. Patients and investigators will be blinded to study treatment. The hypothesis underlying the proposed clinical trial is that exemestane added to standard first line therapy will significantly prolong median progression free survival (PFS).
Timeline
- Start
- 2020-02-13
- Primary completion
- 2023-04-27
- Completion
- 2023-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Exemestane | Small molecule | 25 mg | Oral |